H.C. Wainwright reiterates argenx stock rating on myositis trial update

H.C. Wainwright reiterated a Buy rating on argenx with a $940 price target, about 10% above the current $852.50 share price, and said Vyvgart in myositis could still exceed $1 billion in sales. The firm viewed the shift to separate Phase 3 analyses for IMNM and dermatomyositis as not surprising, while dropping polymyositis due to limited patient enrollment. Sentiment is supported by strong trailing revenue of $4.74 billion and 79% growth, alongside multiple bullish analyst reiterations.

Analysis

The market is still treating this as an execution cleanup story, but the bigger signal is that argenx is narrowing the addressable indication set to the cohort with the highest biologic signal-to-noise ratio. That usually improves probability-adjusted economics even if the headline market size shrinks, because it lowers the odds of a messy, split-label launch and reduces the chance of a weak all-comers readout forcing a retry. In biotech, a cleaner endpoint path often matters more than a slightly larger TAM, especially when commercial adoption depends on physician confidence and payer coverage after approval.

The second-order positive is that this de-risks the FcRn platform narrative beyond neurology. If IMNM validates, argenx can position the asset as a precision autoimmune franchise rather than a single broad-label bet, which should support higher peak penetration in the subpopulation most refractory to steroids/IVIG. That dynamic also pressures smaller autoimmune competitors: a credible label in a rare, high-unmet-need segment tends to pull capital and trial attention away from adjacent early-stage programs that are less advanced or less differentiated.

The main risk is not the near-term stock reaction; it is whether investors extrapolate a tidy IMNM win into broader myositis economics too quickly. DM is still the larger commercial prize, and any weakness there would force the market to haircut long-duration sales assumptions over the next 6-12 months. A second risk is timing: the setup is now event-driven, with a likely long interval before decisive Phase 3 visibility, so the stock can drift on sentiment and analyst target resets rather than fundamentals.

Consensus appears to be underestimating how much a smaller but more severe cohort can accelerate adoption if efficacy is clean. The real miss would be to focus on cohort size instead of treatment-switch behavior, as the most refractory patients often drive disproportionate specialist advocacy and faster formulary acceptance. The move is likely underdone if IMNM remains highly convincing, but overdone if the street is already capitalizing a near-automatic broad myositis franchise into 2026 without evidence for DM.

Key Decisions for Investors

• Maintain/add long ARGX on 3-6 month horizon into weakness; the trade is that a cleaner IMNM path improves probability-adjusted NPV even if label breadth narrows. Use pullbacks from analyst-driven volatility to build, with downside protected by the stock’s existing rerating from positive data optionality.
• Buy ARGX call spreads 6-12 months out to express upside to a successful Phase 3 framing while capping premium if DM disappoints. Prefer spreads over outright calls because the catalyst is binary but timing is long, and implied vol should stay elevated.
• Pair ARGX long vs a basket of earlier-stage autoimmune names with weaker proof-of-concept data over the next 6-9 months. The relative trade benefits if capital keeps rotating toward de-risked assets with clearer regulatory paths.
• If already long, trim only on strength into target upgrades rather than selling the base case; the asymmetric risk is that the market underwrites IMNM as a precision-label win before formal Phase 3 data. Add back on any post-event dip of 5-8% absent new clinical concerns.